Hypoestoxide reduces neuroinflammation and aα-synuclein accumulation in a mouse model of Parkinson's disease

Citations of this article
Mendeley users who have this article in their library.


© 2015 Kim et al.Background: Deposition of aα-synuclein and neuroinflammation are key pathological features of Parkinson's disease (PD). There is no cure for the disease; however, targeting the pathological features might be available to modulate the disease onset and progression. Hypoestoxide (HE) has been demonstrated as a NF-ΚB modulator, thereby acting as a potential anti-inflammatory and anti-cancer drug. Methods: In order to assess the effect of HE in a mouse model of PD, mThy1-aα-syn transgenic mice received intraperitoneal (IP) injections of either vehicle or HE (5 mg/kg) daily for 4 weeks. Results: Treatment of HE decreased microgliosis, astrogliosis, and pro-inflammatory cytokine gene expression in aα-syn transgenic mice. HE administration also prevented the loss of dopaminergic neurons and ameliorated motor behavioral deficits in the aα-syn transgenic mice, and aα-synuclein pathology was significantly reduced by treatment of HE. In addition, increased levels of nuclear phosphorylated NF-ΚB in the frontal cortex of aα-syn transgenic mice were significantly reduced by HE administration. Conclusions: These results support the therapeutic potential of HE for PD and other aα-synuclein-related diseases.




Kim, C., Ojo-Amaize, E., Spencer, B., Rockenstein, E., Mante, M., Desplats, P., … Masliah, E. (2015). Hypoestoxide reduces neuroinflammation and aα-synuclein accumulation in a mouse model of Parkinson’s disease. Journal of Neuroinflammation, 12(1). https://doi.org/10.1186/s12974-015-0455-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free